0
Sign In  | Subscribe
16 March 2010, Vol 152, No. 6>
Summaries for Patients | 16 March 2010

The Effects of Salsalate on Blood Sugar Control in People With Type 2 Diabetes FREE

[+] Article and Author Information

The summary below is from the full report titled “The Effects of Salsalate on Glycemic Control in Patients with Type 2 Diabetes. A Randomized Trial.” It is in the 16 March 2010 issue of Annals of Internal Medicine (volume 152, pages 346-357). The authors are A.B. Goldfine, V. Fonseca, K.A. Jablonski, L. Pyle, M.A. Staten, and S.E. Shoelson, for the TINSAL-T2D (Targeting Inflammation using Salsalate in Type 2 Diabetes) Study Team.


Ann Intern Med. 2010;152(6):I-40. doi:10.7326/0003-4819-152-6-201003160-00001
Text Size: A A A

What is the problem and what is known about it so far?

Drugs to treat type 2 diabetes help lower blood sugar levels. Because most diabetes drugs are not effective enough by themselves or have side effects, people often need to take several drugs to control their blood sugar levels, and scientists are always looking for safer and more effective agents. Salsalate is a drug related to aspirin that has fewer side effects than aspirin. Research has suggested that salsalate reduces blood sugar levels in people with diabetes. Before salsalate can be recommended as a drug that people should take for diabetes, the best dose of the drug needs to be determined, as does its safety when taken over a long time.

Why did the researchers do this particular study?

To compare the ability of different salsalate doses to control blood sugar levels and assess the drug's safety over time.

Who was studied?

108 people with type 2 diabetes.

How was the study done?

After observing participants who received consistent diet and exercise for 4 weeks, the researchers gathered information about participants' health, including their control over blood sugar levels and other measures of their metabolism. They then randomly assigned equal numbers of the participants to 3 different salsalate doses or to placebo in addition to any other diabetes drugs they were receiving. The researchers observed participants for another 14 weeks to assess changes in blood sugar control, weight, and metabolism.

What did the researchers find?

After 14 weeks, participants who received salsalate had better blood sugar control than those who received placebo. They also showed improvement in some measures of risk for heart disease, but they tended to develop more protein in their urine. No single salsalate dose seemed safer or more effective than another.

What were the limitations of the study?

Studying 108 people for 14 weeks moves this area of research forward but does not provide enough evidence to recommend that people use or not use the drug. For example, some measures of risk for heart disease improved, but the increase in urine protein may be an early sign of kidney damage. Too few participants were observed for too short a time to make conclusions.

What are the implications of the study?

Salsalate improves blood sugar control in patients with type 2 diabetes. No single dose seems safer or more effective than another. The safety of the drug will require further testing; additional studies are ongoing.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general jounals
BMJ 2010;341:c5893-c1494.

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Want to Subscribe?

Learn more about subscription options

Register Now for a free account
Advertisement

Related Content

Customize your page view by dragging & repositioning the boxes below.

In the Clinic
Type 2 Diabetes
Ann Intern Med. 2010;152(5):ITC3-1.
Diabetic Ketoacidosis
Ann Intern Med. 2010;152(1):ITC1-1.
Chronic Kidney Disease
Ann Intern Med. 2009;150(3):ITC2-1.
Peripheral Arterial Disease
Ann Intern Med. 2007;146(5):ITC3-1.
Type 2 Diabetes
Ann Intern Med. 2007;146(1):ITC1-1.
Topic Collections
PubMed Articles
Modeling diabetes disease progression and salsalate intervention in Goto-Kakizaki rats.
The Journal of pharmacology and experimental therapeutics Issue date: 2011 Dec
An overview of salsalate as a potential antidiabetic therapy.
Drugs of today (Barcelona, Spain : 1998) Issue date: 2010 Nov

Annals of Internal Medicine

Other Resources

Copyright © 2013 The American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Want to Subscribe?

Learn more about subscription options

Register Now for a free account
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)